Total submissions: 12
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000035676 | SCV000059327 | likely benign | not specified | 2020-08-12 | criteria provided, single submitter | clinical testing | The c.906-7G>T variant in MYBPC3 is classified as likely benign it has been identified in 0.06% (70/122142) of European chromosomes by gnomAD (http://gnomad.broadinstitute.org). Computational splice prediction tools as well as in vitro RNA splicing assays do not predict and impact on splicing (Frisso 2016 PMID: 27834932). ACMG/AMP Criteria applied: BS1, BP4, BP7. |
Gene |
RCV000035676 | SCV000209459 | uncertain significance | not specified | 2013-11-20 | criteria provided, single submitter | clinical testing | The variant is found in HCM panel(s). |
Invitae | RCV001083307 | SCV000623627 | likely benign | Hypertrophic cardiomyopathy | 2024-01-27 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV000625029 | SCV000743568 | likely benign | Hypertrophic cardiomyopathy 4 | 2016-10-27 | criteria provided, single submitter | clinical testing | |
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000625029 | SCV000744862 | benign | Hypertrophic cardiomyopathy 4 | 2017-05-31 | criteria provided, single submitter | clinical testing | |
CHEO Genetics Diagnostic Laboratory, |
RCV000770373 | SCV000901814 | likely benign | Cardiomyopathy | 2021-06-01 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000530779 | SCV001148282 | likely benign | not provided | 2020-12-01 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000770373 | SCV001357000 | likely benign | Cardiomyopathy | 2019-11-21 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000035676 | SCV002600394 | likely benign | not specified | 2022-10-10 | criteria provided, single submitter | clinical testing | Variant summary: MYBPC3 c.906-7G>T alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. 4/4 computational tools predict no significant impact on normal splicing. In a mini gene assay, the variant was reported to have no impact on splicing (Frisso_2016). The variant allele was found at a frequency of 0.00028 in 230196 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in MYBPC3 causing Hypertrophic Cardiomyopathy (0.00028 vs 0.001), allowing no conclusion about variant significance. c.906-7G>T has been reported in the literature in at least one individual affected with Hypertrophic Cardiomyopathy, without strong evidence for causality (Frisso_2016). This report does not provide unequivocal conclusions about association of the variant with Hypertrophic Cardiomyopathy. Seven clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Six submitters classified the variant as likely benign/benign while one classified as VUS. Based on the evidence outlined above, the variant was classified as likely benign. |
Prevention |
RCV003944892 | SCV004766296 | likely benign | MYBPC3-related condition | 2020-05-05 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Clinical Genetics, |
RCV000035676 | SCV001922600 | benign | not specified | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000530779 | SCV001954550 | likely benign | not provided | no assertion criteria provided | clinical testing |